All I can say is WOW ! According to the internal financial information supplied during the due diligence procedures, for the 12 month period ended September 30, 2016, BioGanix had total revenues of US$4M and net earnings of US$1.3M. At September 30, 2016, BioGanix had total assets of US$0.5M. Read more at http://www.stockhouse.com/news/pres...asset-with-us-1-3-million#PVES5GZxuSdZo2jX.99 1.3M$ USD net earnings and only 3M$ CAD market cap ? Must be the most undervalued stock on the TSX-V by far 34M shares out with 24M held by insiders. Float is only 10M shares
Currently trading at 0.12$ At 10x PE we are looking at around 0.60$ on this deal alone without calculating growth etc... This will be fun to ride up
Very nice consolidation here in the 0.12$ range. Stock is now ready for the next leg up. Expect new highs as we get closer than ever to the deal being signe
This is a LOI? and they need to come up with 2.7 Million $ US to get this deal going? RLV needs to have a big financing? Great trading stock of late tho, looking at the volume and interest in the stock.
The deal is pretty much closed, just waiting for TSXV approval really. Huge news on Friday, ducks are lined up. This stock on valuation of earnings alone is worth over 0.50$ once the deal officially closes with say a 0.10$ financing MONTREAL, QUEBEC--(Marketwired - Feb. 10, 2017) - Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the "Company" or "Relevium") a consolidator of e-commerce assets in Health and Wellness in conjunction with its board of directors, is pleased to announce the addition of Dr. Tina Sampalis to the Company's Board of Directors. Tina Sampalis, M.D., Ph.D., is an oncology surgeon trained in physiology at McGill University in Montreal, medicine at the University of Patras (Greece), dermatology at Göttingen University (Germany) and Marselisborg University (Denmark), pediatric, general and oncology surgery at the University of Athens (Greece), graduate training (Ph.D.) in Surgical Research at the University of Athens and a second Ph.D. in Epidemiology and Experimental Surgery at McGill University. Dr. Sampalis' leading work in Nutraceuticals includes Neptune Technologies & Bioressources, where she discovered one of the primary reasons krill oil is so beneficial to human health: Phospholipids. Dr. Sampalis is the named inventor of Neptune's composition and application patents. As the former President of Acasti Pharma Inc. she led the development of a novel patented active pharmaceutical ingredient targeting the prevention and treatment of hypertriglyceridemia and cardio metabolic-disorders. She is the Founder and President of the AGOO Children's Health & Wellness Center, a state-of-the-art multidisciplinary comprehensive, pediatric-adolescent medical center and accredited McGill University teaching site in Quebec. Dr. Sampalis has received several international scholarships and awards for her work on the clinical implementation of retinols for skin and breast cancer, including the Helen Hutchison Award for geriatric medicine. Her work on scintimammography resulted in her appointment at the International Educational Speakers Bureau, the Canadian and U.S. Faculty of Medical Speakers for Breast Imaging. As an international scholar, Dr. Sampalis leads the development and implementation of innovative micro-invasive and stereotactic robotic surgical techniques for breast cancer, for which a U.S. and Canadian patent application has been filed. She is a member of the American Association of Naturopathic Medicine. Dr. Sampalis has published papers in multiple peer-reviewed publications. She was named one of the 10 most successful women in Quebec (Les Affaires, 18-24 September 2010) and one of the 100 most successful globally by the Princeton Global Network. Relevium Technologies Inc. (TSX.V - "RLV") President and CEO, Aurelio Useche, stated, "We are very honored to have Dr. Sampalis join our Company. The addition of Dr. Sampalis closes the value chain by providing deep expertise in scientific and evidence based nutraceutical and medical trends, which can be leveraged through the consolidation of e-commerce assets such as BioGanix as announced on December 22, 2016."
Sleeky - though I like the deal. My concern is how the funds will be raised for it. There are rumors that the Private Placement is going to come in at 10-12 cents. That would limit upside in the short term significantly - can you comment on this?